Is American Express a Buy, Sell or Hold?
American Express (NYSE:AXP) holds a notable place in Warren Buffett’s…
Sell
24
BMEA Quote, Financials, Valuation and Earnings
Last price:
$1.70
Seasonality move
:
19.33%
Day range:
$1.60 - $1.78
52-week range:
$1.53 - $13.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.23x
Volume:
868.4K
Avg. volume:
724.6K
1-year change:
-85.3%
Market cap:
$63.5M
Revenue:
--
EPS (TTM):
-$4.01
Analysts' Opinion
-
Consensus RatingBiomea Fusion has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.25, Biomea Fusion has an estimated upside of 1275.74% from its current price of $1.69.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $1.69.
Fair Value
-
According to the consensus of 6 analysts, Biomea Fusion has 1275.74% upside to fair value with a price target of $23.25 per share.
BMEA vs. S&P 500
-
Over the past 5 trading days, Biomea Fusion has underperformed the S&P 500 by -0.82% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Biomea Fusion does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biomea Fusion has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Biomea Fusion reported revenues of --.
Earnings Growth
-
Biomea Fusion has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Biomea Fusion reported earnings per share of -$0.91.
Enterprise value:
5.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.04x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$83.6M | -$126.1M | -$144.1M | -$37.3M | -$30.1M | |
| EBITDA | -$82.9M | -$124.6M | -$142.3M | -$36.9M | -$29.6M | |
| Diluted EPS | -$2.79 | -$3.46 | -$3.84 | -$0.98 | -$0.81 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $62.2M | $176.6M | $117.8M | $179.2M | $68.3M | |
| Total Assets | $62.5M | $185.7M | $129.3M | $199.9M | $79.9M | |
| Current Liabilities | $1.6M | $4.6M | $19.1M | $22.9M | $21.7M | |
| Total Liabilities | $57.4M | $6.9M | $20.8M | $30.7M | $28.4M | |
| Total Equity | $5.2M | $178.8M | $108.5M | $169.2M | $51.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62.4M | -$96.6M | -$119.9M | -$22.8M | -$30M | |
| Cash From Investing | $27.3M | -$2.2M | -$362K | -$8K | -$82K | |
| Cash From Financing | $1.2M | $163.8M | $1.7M | $622K | $413K | |
| Free Cash Flow | -$63.4M | -$100M | -$120.3M | -$22.8M | -$30.1M | |
BMEA
Sector
Market Cap
$63.5M
$35M
Price % of 52-Week High
12.58%
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-85.3%
-41.61%
Beta (5-Year)
--
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.71
200-day SMA
Sell
Level
$5.73
Bollinger Bands (100)
Sell
Level
2.36 - 5.34
Chaikin Money Flow
Sell
Level
-28.9M
20-day SMA
Sell
Level
$2.08
Relative Strength Index (RSI14)
Sell
Level
35.26
ADX Line
Sell
Level
33.2
Williams %R
Neutral
Level
-78.9474
50-day SMA
Sell
Level
$2.72
MACD (12, 26)
Sell
Level
-0.32
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
20M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Stock Forecast FAQ
In the current month, BMEA has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BMEA average analyst price target in the past 3 months is $23.25.
-
Where Will Biomea Fusion Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biomea Fusion share price will rise to $23.25 per share over the next 12 months.
-
What Do Analysts Say About Biomea Fusion?
Analysts are divided on their view about Biomea Fusion share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biomea Fusion is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Biomea Fusion's Price Target?
The price target for Biomea Fusion over the next 1-year time period is forecast to be $23.25 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BMEA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biomea Fusion is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BMEA?
You can purchase shares of Biomea Fusion via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biomea Fusion shares.
-
What Is The Biomea Fusion Share Price Today?
Biomea Fusion was last trading at $1.70 per share. This represents the most recent stock quote for Biomea Fusion. Yesterday, Biomea Fusion closed at $1.69 per share.
-
How To Buy Biomea Fusion Stock Online?
In order to purchase Biomea Fusion stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Baidu Stock a Sleeper AI Winner?
Although the recent policy decisions have gripped the market now,…
JPMorgan Is The Rally Over?
JPMorgan Chase (NYSE:JPM) share price is up 29% over the…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 19
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 19
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 19
Global Payments [GPN] is down 17.44% over the past day.
